Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP).
This report updates the 2001 recommendations by the Advisory Committee on Immunization Practices (ACIP) regarding the use of influenza vaccine and antiviral agents (MMWR 2001;50 [No. RR-4]:1-44). The 2002 recommendations include new or updated information regarding 1) the timing of influenza vaccination by risk group; 2) influenza vaccine for children aged 6-23 months; 3) the 2002-2003 trivalent vaccine virus strains: A/Moscow/10/99 (H3N2)-like, A/New Caledonia/20/99 (H1N1)-like, and B/Hong Kong/330/2001-like strains; and 4) availability of certain influenza vaccine doses with reduced thimerosal content. A link to this report and other information related to influenza can be accessed at the website for the Influenza Branch, Division of Viral and Rickettsial Diseases, National Center for Infectious Diseases, CDC, at http://www.cdc.gov/ncidod/diseases/flu/fluvirus.htm.
Bridges
Carolyn B
CB
Division of Viral and Rickettsial Diseases, National Center for Infectious Diseases, USA.
Fukuda
Keiji
K
Uyeki
Timothy M
TM
Cox
Nancy J
NJ
Singleton
James A
JA
D000081:Acetamides / Q000627:therapeutic use; D000293:Adolescent; D000328:Adult; D000368:Aged; D000547:Amantadine / Q000627:therapeutic use; D000998:Antiviral Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D003362:Cost-Benefit Analysis; D006146:Guanidines; D006801:Humans; D007223:Infant; D009980:Influenza A virus / Q000276:immunology; D009981:Influenza B virus / Q000276:immunology; D007252:Influenza Vaccines / Q000008:administration & dosage* / Q000009:adverse effects / Q000191:economics / Q000276:immunology; D007251:Influenza, Human / Q000175:diagnosis / Q000191:economics / Q000453:epidemiology / Q000517:prevention & control*; D008875:Middle Aged; D053139:Oseltamivir; D011714:Pyrans; D012299:Rimantadine / Q000627:therapeutic use; D012307:Risk Factors; D012794:Sialic Acids / Q000627:therapeutic use; D014481:United States / Q000453:epidemiology; D014611:Vaccination / Q000191:economics / Q000592:standards; D053243:Zanamivir
D000081:Acetamides; D000998:Antiviral Agents; D006146:Guanidines; D007252:Influenza Vaccines; D011714:Pyrans; D012794:Sialic Acids; D012299:Rimantadine; D053139:Oseltamivir; D000547:Amantadine; D053243:Zanamivir